Quest Diagnostics (DGX) is higher today after releasing first-quarter 2026 financial results and raising its full-year 2026 revenue and EPS outlook. The guidance lift is the primary catalyst behind the move, signaling stronger-than-expected operating momentum early in the year.

For the quarter ended March 31, 2026, Quest reported diluted EPS of $2.24, up 15.5% versus the prior year period, and adjusted diluted EPS of $2.50, up 13.1%. Alongside the results, Quest increased its full-year 2026 guidance for both revenue and earnings, which tends to re-rate sentiment quickly for defensive healthcare services names when the market is uncertain about forward demand.

DGX entered the day with investors focused on whether utilization trends, advanced diagnostics mix, and integration of prior deals could translate into margin expansion and a steadier 2026 outlook. A quarter that supports higher full-year targets reduces downside risk to estimates and can prompt incremental buying from investors looking for earnings durability.

The next driver is whether Quest can sustain the pace implied by the higher 2026 outlook through the remaining quarters, particularly on margins and cost discipline. Investors will also watch management commentary for demand signals in routine testing, progress in advanced diagnostics offerings, and any updates on capital allocation priorities that could support per-share earnings.